Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Blog Article

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies.Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited.In this report, we describe a patient Nails with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA.We also found a KARAMBIT flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib.

This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.